Company profile
Curative Biosciences, Inc.
OTC: CBDX · Healthcare · Drug Manufacturers - Specialty & Generic
#1018 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 8GM —SS 38
v0.1 · 25/100 weight · pillars only
↑ listing tenure, net margin · ↓ balance-sheet leverage, return on assets
Methodology →Revenue TTM
$162.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$53.2k
Employees
6
as of 2026-08-02
Market cap
$25.8k
as of 2026-08-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$162.0k$162.0k2013
Net income-$53.2k-$53.2k2017
Operating income-$53.2k-$53.2k2017
Total assets$2.3k$2.3k2017
Liabilities$633.1k$633.1k2017
Equity-$630.8k-$630.8k2017
Revenue trend
FY2012 – FY2013 · USD
FY12
FY12
FY13
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Curative Biosciences, Inc.’s revenue?
Curative Biosciences, Inc. booked $162.0k in FY2013 revenue, contracting 51% year over year — slower than 82% of Healthcare companies we track, at a -32.8% net margin.
Peers · Healthcare
Lisata Therapeutics, Inc.39DInnerScope Hearing Technologies, Inc.——Kalaris Therapeutics Inc30DZIVO Bioscience, Inc.——Cannabis Strategic Ventures——Anthera Pharmaceuticals, Inc.——Neighbors
Miami-Dade →Key facts
CEOMarcel Gamma
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMiami, FL
ExchangeOTC: CBDX
Employees6
IPO date2004-08-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.